Wereldwijd initiatief omtrent harmonisatie naamgeving radionuclidentherapie

In een van de bijeenkomsten van het Nuclear Medicine Global Initiative (NMGI) in 2023 is gesproken over de harmonisatie van de naamgeving van radionuclidentherapie. Het NMGI heeft een wereldwijde enquête uitgezet over dit onderwerp.

De enquête kan via deze link tot en met 31 januari worden ingevuld. Invullen kost niet meer dan enkele minuten.

Voor meer informatie vanuit de SNMMI (Society of Nuclear Medicine & Molecular Imaging), lees hieronder verder.

‘In recent years therapeutic nuclear medicine has shown tremendous promise and enjoyed remarkable growth in the field of oncology and certain non-oncological conditions, resulting in improved patient outcomes. There are significant inconsistencies in the use of terminologies. A recent search demonstrated that more than 15 different terminologies are in existence. Inconsistent use of terminology can have several negative consequences, including awareness and acceptance by the patients and referring providers, confusion and miscommunication, difficulty in literature review, clinical implementation, regulatory issues, research and development implications, patient education and informed consent, etc.

This dilemma was discussed at length at one of the nuclear medicine global initiatives (NMGI) meetings in 2023. NMGI was established approximately 13 years ago with the goals to encourage global collaboration in nuclear medicine education, to harmonize procedure guidelines and other polices and to improve quality and safety. NMGI comprises several national and international nuclear medicine organizations which have worked together over the years, resulting in successful completion of initiatives such as standardization of administered activities in pediatric nuclear medicine, global issues of radiopharmaceutical access and availability and a challenging educational paradigm in nuclear medicine involving theranostics.
NMGI, at a meeting in 2023, approved an attempt at harmonization of terminology of therapeutic nuclear medicine as one of the projects. We are therefore reaching out to you for assistance. We do recognize that it will be almost impossible to enforce the use of a single, consistent terminology globally and that therapeutic nuclear medicine is comprised of a heterogenous group of radionuclides and radiopharmaceuticals necessitating the use of certain subcategories in given situations, such as PRRT or radioimmunotherapy. However, a broader consensus around the recommended use of the umbrella terminology would go a long way in avoiding confusion and miscommunication and improving clinical implementation, literature review and acceptance by patients and their referring providers.

Following NMGI’s approval of this terminology harmonization project several meetings took place seeking input from leading experts in the field. In addition, we took additional steps to narrow down the terminology from more than 15 that are in existence to the most used three leading contenders. Our goal is to reach out to various experts, including but not limited to physicians, physicists, radiochemists, radiopharmacists, industry representatives, regulatory agencies, patient advocates, and international journal editors to seek their input on down selecting the three terminologies to the one they would recommend for use, the reason for the choice and pros and cons of each choice. We plan to summarize the survey.’